Get the Stockscreener App
15.57
0.58%
0.09
After Hours:
15.70
0.13
+0.83%
Pharvaris Nv stock is traded at $15.57, with a volume of 19,232.
It is up +0.58% in the last 24 hours and up +0.06% over the past month.
See More
Previous Close:
$15.48
Open:
$15.64
24h Volume:
19,232
Relative Volume:
0.46
Market Cap:
$844.41M
Revenue:
-
Net Income/Loss:
$-143.59M
P/E Ratio:
-5.5142
EPS:
-2.8236
Net Cash Flow:
$-119.47M
1W Performance:
+0.71%
1M Performance:
+0.06%
6M Performance:
-16.02%
1Y Performance:
-33.74%
1-Day Range:
$15.40
$16.18
1-Week Range:
$15.10
$16.18
52-Week Range:
$14.14
$25.50
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
15.57 | 844.41M | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.55 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.83 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
593.47 | 36.20B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.02 | 35.08B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
262.60 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
(PHVS) Technical Data - Stock Traders Daily
Can Pharvaris Impress Investors at Upcoming Leerink Conference? - StockTitan
How to Take Advantage of moves in (PHVS) - Stock Traders Daily
We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth - Yahoo Finance
(PHVS) Trading Report - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Sees Significant Increase in Short Interest - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Gap DownWhat's Next? - MarketBeat
(PHVS) Investment Analysis - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Price Target Raised to $55.00 - MarketBeat
Where are the Opportunities in (PHVS) - Stock Traders Daily
Barclays PLC Purchases New Holdings in Pharvaris (NASDAQ:PHVS) - Defense World
Why Is Andreas Halvorsen Bullish On Pharvaris N.V. (PHVS) Now? - Insider Monkey
FY2026 EPS Estimates for Pharvaris Decreased by Analyst - Defense World
Leerink Partnrs Brokers Cut Earnings Estimates for Pharvaris - MarketBeat
Pharvaris (NASDAQ:PHVS) Trading Up 5.3%What's Next? - MarketBeat
How To Trade (PHVS) - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Stock Price Down 11.7%Here's Why - MarketBeat
Pharvaris Advances Phase 3 HAE Programs, Expands Pipeline Into Acquired Angioedema Treatment - StockTitan
Geode Capital Management LLC Boosts Holdings in Pharvaris (NASDAQ:PHVS) - Defense World
Barclays PLC Takes Position in Pharvaris (NASDAQ:PHVS) - Defense World
(PHVS) Long Term Investment Analysis - Stock Traders Daily
Jane Street Group LLC Makes New Investment in Pharvaris (NASDAQ:PHVS) - Defense World
Jane Street Group LLC Acquires Shares of 28,418 Pharvaris (NASDAQ:PHVS) - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
State Street Corp Purchases New Shares in Pharvaris (NASDAQ:PHVS) - Defense World
53,980 Shares in Pharvaris (NASDAQ:PHVS) Bought by State Street Corp - MarketBeat
Pharvaris (NASDAQ:PHVS) Trading Down 3.5%Here's Why - MarketBeat
Pharvaris: Despite 30% Decline, Still Fair At Best (NASDAQ:PHVS) - Seeking Alpha
Pharvaris (NASDAQ:PHVS) Sees Large Decrease in Short Interest - MarketBeat
Trend Tracker for (PHVS) - Stock Traders Daily
Pharvaris (PHVS) Shares Cross Above 200 DMA - Nasdaq
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $906,000 in Pharvaris (NASDAQ:PHVS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New $906,000 Investment in Pharvaris (NASDAQ:PHVS) - MarketBeat
Learn to Evaluate (PHVS) using the Charts - Stock Traders Daily
Pharvaris (PHVS) Price Target Increased by 38.65% to 32.93 - MSN
Pharvaris price target lowered to $46 from $50 at JMP Securities - Yahoo Finance
Long Term Trading Analysis for (PHVS) - Stock Traders Daily
Pharvaris Reports Q3 2024 Progress and Financials - TipRanks
Pharvaris Reports 93% HAE Attack Reduction in Trial Data, Plans Phase 3 Study | PHVS Stock News - StockTitan
Pharvaris to Present HAE Treatment Progress at Guggenheim Healthcare Conference | PHVS Stock News - StockTitan
PHVS Makes Notable Cross Below Critical Moving Average - Nasdaq
Axonis Therapeutics Announces $115 Million Series A Financing - Financial Times
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting - StockTitan
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.46%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):